Assessing the impact of neutron relative biological effectiveness on all solid cancer mortality risks in the Japanese atomic bomb survivors

References

• Brenner AV, Preston DL, Sakata R, Cologne J, Sugiyama H, Utada M, Cahoon EK, Grant E, Mabuchi K, Ozasa K. 2022. Comparison of all solid cancer mortality and incidence dose–response in the life span study of atomic bomb survivors, 1958–2009. Radiat Res. 197(5):491–508. doi:10.1667/RADE-21-00059.1
   PubMed Web of Science ®Google Scholar
• Cordova KA, Cullings HM. 2019. Assessing the relative biological effectiveness of neutrons across organs of varying depth among the atomic bomb survivors. Radiat Res. 192(4):380–387. doi:10.1667/RR15391.1
   PubMed Web of Science ®Google Scholar
• Cullings HM, Grant EJ, Egbert SD, Watanabe T, Oda T, Nakamura F, Yamashita T, Fuchi H, Funamoto S, Marumo K, et al. 2017. DS02R1: improvements to atomic bomb survivors’ input data and implementation of dosimetry system 2002 (DS02) and resulting changes in estimated doses. Health Phys. 112(1):56–97. doi:10.1097/HP.0000000000000598
   PubMed Web of Science ®Google Scholar
• Fieller EC. 1940. The biological standardization of insulin. Suppl J R Stat Soc. 7(1):1–64. doi:10.2307/2983630
   Google Scholar
• Grant EJ, Brenner A, Sugiyama H, Sakata R, Sadakane A, Utada M, Cahoon EK, Milder CM, Soda M, Cullings HM, et al. 2017. Solid cancer incidence among the life span study of atomic bomb survivors: 1958–2009. Radiat Res. 188(3):370–371. doi:10.1667/RR14492.1
   PubMed Web of Science ®Google Scholar
• Griffin K, Paulbeck C, Bolch W, Cullings H, Egbert S, Funamoto S, Sato T, Endo A, Hertel N, Lee C. 2019. Dosimetric impact of a new computational voxel phantom series for the Japanese atomic bomb survivors: children and adults. Radiat Res. 191(4):369–379. doi:10.1667/RR15267.1
   PubMed Web of Science ®Google Scholar
• Griffin KT, Sato T, Funamoto S, Chizhov K, Domal S, Paulbeck C, Bolch W, Cullings HM, Egbert S, Endo A, et al. 2022. Japanese pediatric and adult atomic bomb survivor dosimetry: potential improvements using the J45 phantom series and modern Monte Carlo transport. Radiat Environ Biophys. 61(1):73–86. doi:10.1007/s00411-021-00946-2
   PubMed Web of Science ®Google Scholar
• Hafner L, Walsh L, Rühm W. 2023. Assessing the impact of different neutron RBEs on the all solid cancer radiation risks obtained from the Japanese A-bomb survivors data. Int J Radiat Biol. 99(4):629–643. doi:10.1080/09553002.2022.2117871
   PubMed Web of Science ®Google Scholar
• Hafner L, Walsh L, Schneider U. 2021. Cancer incidence risks above and below 1 Gy for radiation protection in space. Life Sci Space Res. 28:41–56. doi:10.1016/j.lssr.2020.09.001
   Google Scholar
• ICRP. 2003. Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (wR). ICRP Publication 92. Ann ICRP 33.
   Google Scholar
• ICRP. 2007. ICRP recommendations of the international commission on radiological protection. ICRP Publication 103. Ann ICRP 37.
   Google Scholar
• Kellerer AM, Rühm W, Walsh L. 2006. Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors. Health Phys. 90(6):554–564. doi:10.1097/01.HP.0000184917.94232.cd
   PubMed Web of Science ®Google Scholar
• Kellerer AM, Walsh L. 2001. Risk estimating for fast neutrons with regard to solid cancer. Radiat Res. 156(6):708–717. doi:10.1667/0033-7587(2001)156[0708:reffnw[PMC]2.0.co;2]
   PubMed Web of Science ®Google Scholar
• Little MP, Muirhead CR. 2000. Derivation of low-dose extrapolation factors from analysis of curvature in the cancer incidence dose response in Japanese atomic bomb survivors. Int J Radiat Biol. 76(7):939–953. doi:10.1080/09553000050050954
   PubMed Web of Science ®Google Scholar
• Little MP, Pawel D, Misumi M, Hamada N, Cullings HM, Wakeford R, Ozasa K. 2020. Lifetime mortality risk from cancer and circulatory disease predicted from the Japanese atomic bomb survivor life span study data taking account of dose measurement error. Radiat Res. 194(3):259–276. doi:10.1667/RR15571.1
   PubMed Web of Science ®Google Scholar
• Little MP. 1997. Estimates of neutron relative biological effectiveness derived from the Japanese atomic bomb survivors. Int J Radiat Biol. 72(6):715–726. doi:10.1080/095530097142870
   PubMed Web of Science ®Google Scholar
• Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, Sakata R, Sugiyama H, Kodama K. 2012. Studies of the mortality of atomic bomb survivors, report 14, 1950–2003: an overview of cancer and noncancer disease. Radiat Res. 177(3):229–243. doi:10.1667/rr2629.1
   PubMed Web of Science ®Google Scholar
• Preston DL, Pierce DA, Shimizu Y, Cullings HM, Fujita S, Funamoto S, Kodama K. 2004. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res. 162(4):377–389. doi:10.1667/rr3232
   PubMed Web of Science ®Google Scholar
• Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. 2007. Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiat Res. 168(1):1–64. doi:10.1667/RR0763.1
   PubMed Web of Science ®Google Scholar
• Rühm W, Walsh L. 2007. Current risk estimates based on the A-bomb survivors data—a discussion in terms of the ICRP recommendations on the neutron weighting factor. Radiat Prot Dosimetry. 126(1–4):423–431. doi:10.1093/rpd/ncm087
   PubMed Web of Science ®Google Scholar
• Satoh K, Yasuda H, Kawakami H, Tashiro S. 2018. Relative biological effectiveness of neutrons derived from the excess relative risk model with the atomic bomb survivors data managed by Hiroshima University. Radiat Prot Dosimetry. 180(1–4):346–350. doi:10.1093/rpd/ncx173
   PubMed Web of Science ®Google Scholar
• Walsh L. 2013. Neutron relative biological effectiveness for solid cancer incidence in the Japanese A-bomb survivors: an analysis considering the degree of independent effects from gamma-ray and neutron absorbed doses with hierarchical partitioning. Radiat Environ Biophys. 52(1):29–36. doi:10.1007/s00411-012-0445-6
   PubMed Web of Science ®Google Scholar